Loading…
Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions
Individuals with neurofibromatosis type 1 (NF1) have a high incidence of osteoporosis and osteopenia. However, understanding of the cellular and molecular basis of these sequelae is incomplete. Osteoclasts are specialized myeloid cells that are the principal bone-resorbing cells of the skeleton. We...
Saved in:
Published in: | The Journal of clinical investigation 2006-11, Vol.116 (11), p.2880-2891 |
---|---|
Main Authors: | , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c2812-c26a76a5f84b758f962fc29f1513a7cd917c85f433d235bbfbd94e283f1f97ee3 |
---|---|
cites | cdi_FETCH-LOGICAL-c2812-c26a76a5f84b758f962fc29f1513a7cd917c85f433d235bbfbd94e283f1f97ee3 |
container_end_page | 2891 |
container_issue | 11 |
container_start_page | 2880 |
container_title | The Journal of clinical investigation |
container_volume | 116 |
creator | Yang, Feng-Chun Chen, Shi Robling, Alexander G Yu, Xijie Nebesio, Todd D Yan, Jincheng Morgan, Trent Li, Xiaohong Yuan, Jin Hock, Janet Ingram, David A Clapp, D Wade |
description | Individuals with neurofibromatosis type 1 (NF1) have a high incidence of osteoporosis and osteopenia. However, understanding of the cellular and molecular basis of these sequelae is incomplete. Osteoclasts are specialized myeloid cells that are the principal bone-resorbing cells of the skeleton. We found that Nf1(+/-) mice contain elevated numbers of multinucleated osteoclasts. Both osteoclasts and osteoclast progenitors from Nf1(+/-) mice were hyperresponsive to limiting concentrations of M-CSF and receptor activator of NF-kappaB ligand (RANKL) levels. M-CSF-stimulated p21(ras)-GTP and Akt phosphorylation was elevated in Nf1(+/-) osteoclasts associated with gains of function in survival, proliferation, migration, adhesion, and lytic activity. These gains of function are associated with more severe bone loss following ovariectomy as compared with that in syngeneic WT mice. Intercrossing Nf1(+/-) mice and mice deficient in class 1(A) PI3K (p85alpha) restored elevated PI3K activity and Nf1(+/-) osteoclast functions to WT levels. Furthermore, in vitro-differentiated osteoclasts from NF1 patients also displayed elevated Ras/PI3K activity and increased lytic activity analogous to those in murine Nf1(+/-) osteoclasts. Collectively, our results identify a what we believe to be a novel cellular and biochemical NF1-haploinsufficient phenotype in osteoclasts that has potential implications for the pathogenesis of NF1 bone disease. |
doi_str_mv | 10.1172/jci29092 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1616197</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68107939</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2812-c26a76a5f84b758f962fc29f1513a7cd917c85f433d235bbfbd94e283f1f97ee3</originalsourceid><addsrcrecordid>eNpVkcFq3DAQhnVoaJJtoU9QdCq9bKKRbMu6FMqSJpsG2kN7FmNZ6irYkiPJgbxAnzveZEkbBmYO8_HPz_yEfAB2BiD5-a3xXDHF35ATxjislRTtMTnN-ZYxqKq6ekuOQbJatAJOyN-rh8kmNMXfY_Ex0OjoxCFhphh6-nMrvlMT454plpZIcSg20XFOPtgnZDePGGiwc4rOdymOWGL2mZZFmMJ6h9MQfcizc954GwqNudhoBsyFujmY_dX8jhw5HLJ9f5gr8vvbxa_N1frmx-V28_VmbXgLfOkNygZr11adrFunGu4MVw5qEChNr0CatnaVED0Xdde5rleV5a1w4JS0VqzIl2fdae5G25vFT8JBT8mPmB50RK9fb4Lf6T_xXkOz1PLKFfl0EEjxbra56NFnY4cBg41z1k0LTCqhFvDzM2hSzDlZ93IEmN4Hpa8326egFvTj_6b-gYeUxCOF75RK</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68107939</pqid></control><display><type>article</type><title>Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions</title><source>PubMed Central</source><source>EZB Electronic Journals Library</source><creator>Yang, Feng-Chun ; Chen, Shi ; Robling, Alexander G ; Yu, Xijie ; Nebesio, Todd D ; Yan, Jincheng ; Morgan, Trent ; Li, Xiaohong ; Yuan, Jin ; Hock, Janet ; Ingram, David A ; Clapp, D Wade</creator><creatorcontrib>Yang, Feng-Chun ; Chen, Shi ; Robling, Alexander G ; Yu, Xijie ; Nebesio, Todd D ; Yan, Jincheng ; Morgan, Trent ; Li, Xiaohong ; Yuan, Jin ; Hock, Janet ; Ingram, David A ; Clapp, D Wade</creatorcontrib><description>Individuals with neurofibromatosis type 1 (NF1) have a high incidence of osteoporosis and osteopenia. However, understanding of the cellular and molecular basis of these sequelae is incomplete. Osteoclasts are specialized myeloid cells that are the principal bone-resorbing cells of the skeleton. We found that Nf1(+/-) mice contain elevated numbers of multinucleated osteoclasts. Both osteoclasts and osteoclast progenitors from Nf1(+/-) mice were hyperresponsive to limiting concentrations of M-CSF and receptor activator of NF-kappaB ligand (RANKL) levels. M-CSF-stimulated p21(ras)-GTP and Akt phosphorylation was elevated in Nf1(+/-) osteoclasts associated with gains of function in survival, proliferation, migration, adhesion, and lytic activity. These gains of function are associated with more severe bone loss following ovariectomy as compared with that in syngeneic WT mice. Intercrossing Nf1(+/-) mice and mice deficient in class 1(A) PI3K (p85alpha) restored elevated PI3K activity and Nf1(+/-) osteoclast functions to WT levels. Furthermore, in vitro-differentiated osteoclasts from NF1 patients also displayed elevated Ras/PI3K activity and increased lytic activity analogous to those in murine Nf1(+/-) osteoclasts. Collectively, our results identify a what we believe to be a novel cellular and biochemical NF1-haploinsufficient phenotype in osteoclasts that has potential implications for the pathogenesis of NF1 bone disease.</description><identifier>ISSN: 0021-9738</identifier><identifier>DOI: 10.1172/jci29092</identifier><identifier>PMID: 17053831</identifier><language>eng</language><publisher>United States: American Society for Clinical Investigation</publisher><subject>Animals ; Bone Resorption ; Cell Differentiation ; Cell Nucleus - genetics ; Cell Survival ; Cells, Cultured ; Chromones - pharmacology ; Enzyme Activation ; GTP Phosphohydrolases - metabolism ; Haplotypes ; Humans ; Macrophage Colony-Stimulating Factor - pharmacology ; Mice ; Mice, Knockout ; Morpholines - pharmacology ; Neurofibromatosis 1 - genetics ; Neurofibromatosis 1 - metabolism ; Neurofibromatosis 1 - pathology ; Neurofibromin 1 - deficiency ; Neurofibromin 1 - genetics ; Neurofibromin 1 - metabolism ; Osteoclasts - drug effects ; Osteoclasts - metabolism ; Osteoclasts - pathology ; Phosphatidylinositol 3-Kinases - genetics ; Phosphatidylinositol 3-Kinases - metabolism ; Proto-Oncogene Proteins p21(ras) - metabolism ; RANK Ligand - pharmacology ; Stem Cells - metabolism ; Stem Cells - pathology</subject><ispartof>The Journal of clinical investigation, 2006-11, Vol.116 (11), p.2880-2891</ispartof><rights>Copyright © 2006, American Society for Clinical Investigation 2006</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2812-c26a76a5f84b758f962fc29f1513a7cd917c85f433d235bbfbd94e283f1f97ee3</citedby><cites>FETCH-LOGICAL-c2812-c26a76a5f84b758f962fc29f1513a7cd917c85f433d235bbfbd94e283f1f97ee3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1616197/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1616197/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17053831$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yang, Feng-Chun</creatorcontrib><creatorcontrib>Chen, Shi</creatorcontrib><creatorcontrib>Robling, Alexander G</creatorcontrib><creatorcontrib>Yu, Xijie</creatorcontrib><creatorcontrib>Nebesio, Todd D</creatorcontrib><creatorcontrib>Yan, Jincheng</creatorcontrib><creatorcontrib>Morgan, Trent</creatorcontrib><creatorcontrib>Li, Xiaohong</creatorcontrib><creatorcontrib>Yuan, Jin</creatorcontrib><creatorcontrib>Hock, Janet</creatorcontrib><creatorcontrib>Ingram, David A</creatorcontrib><creatorcontrib>Clapp, D Wade</creatorcontrib><title>Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions</title><title>The Journal of clinical investigation</title><addtitle>J Clin Invest</addtitle><description>Individuals with neurofibromatosis type 1 (NF1) have a high incidence of osteoporosis and osteopenia. However, understanding of the cellular and molecular basis of these sequelae is incomplete. Osteoclasts are specialized myeloid cells that are the principal bone-resorbing cells of the skeleton. We found that Nf1(+/-) mice contain elevated numbers of multinucleated osteoclasts. Both osteoclasts and osteoclast progenitors from Nf1(+/-) mice were hyperresponsive to limiting concentrations of M-CSF and receptor activator of NF-kappaB ligand (RANKL) levels. M-CSF-stimulated p21(ras)-GTP and Akt phosphorylation was elevated in Nf1(+/-) osteoclasts associated with gains of function in survival, proliferation, migration, adhesion, and lytic activity. These gains of function are associated with more severe bone loss following ovariectomy as compared with that in syngeneic WT mice. Intercrossing Nf1(+/-) mice and mice deficient in class 1(A) PI3K (p85alpha) restored elevated PI3K activity and Nf1(+/-) osteoclast functions to WT levels. Furthermore, in vitro-differentiated osteoclasts from NF1 patients also displayed elevated Ras/PI3K activity and increased lytic activity analogous to those in murine Nf1(+/-) osteoclasts. Collectively, our results identify a what we believe to be a novel cellular and biochemical NF1-haploinsufficient phenotype in osteoclasts that has potential implications for the pathogenesis of NF1 bone disease.</description><subject>Animals</subject><subject>Bone Resorption</subject><subject>Cell Differentiation</subject><subject>Cell Nucleus - genetics</subject><subject>Cell Survival</subject><subject>Cells, Cultured</subject><subject>Chromones - pharmacology</subject><subject>Enzyme Activation</subject><subject>GTP Phosphohydrolases - metabolism</subject><subject>Haplotypes</subject><subject>Humans</subject><subject>Macrophage Colony-Stimulating Factor - pharmacology</subject><subject>Mice</subject><subject>Mice, Knockout</subject><subject>Morpholines - pharmacology</subject><subject>Neurofibromatosis 1 - genetics</subject><subject>Neurofibromatosis 1 - metabolism</subject><subject>Neurofibromatosis 1 - pathology</subject><subject>Neurofibromin 1 - deficiency</subject><subject>Neurofibromin 1 - genetics</subject><subject>Neurofibromin 1 - metabolism</subject><subject>Osteoclasts - drug effects</subject><subject>Osteoclasts - metabolism</subject><subject>Osteoclasts - pathology</subject><subject>Phosphatidylinositol 3-Kinases - genetics</subject><subject>Phosphatidylinositol 3-Kinases - metabolism</subject><subject>Proto-Oncogene Proteins p21(ras) - metabolism</subject><subject>RANK Ligand - pharmacology</subject><subject>Stem Cells - metabolism</subject><subject>Stem Cells - pathology</subject><issn>0021-9738</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNpVkcFq3DAQhnVoaJJtoU9QdCq9bKKRbMu6FMqSJpsG2kN7FmNZ6irYkiPJgbxAnzveZEkbBmYO8_HPz_yEfAB2BiD5-a3xXDHF35ATxjislRTtMTnN-ZYxqKq6ekuOQbJatAJOyN-rh8kmNMXfY_Ex0OjoxCFhphh6-nMrvlMT454plpZIcSg20XFOPtgnZDePGGiwc4rOdymOWGL2mZZFmMJ6h9MQfcizc954GwqNudhoBsyFujmY_dX8jhw5HLJ9f5gr8vvbxa_N1frmx-V28_VmbXgLfOkNygZr11adrFunGu4MVw5qEChNr0CatnaVED0Xdde5rleV5a1w4JS0VqzIl2fdae5G25vFT8JBT8mPmB50RK9fb4Lf6T_xXkOz1PLKFfl0EEjxbra56NFnY4cBg41z1k0LTCqhFvDzM2hSzDlZ93IEmN4Hpa8326egFvTj_6b-gYeUxCOF75RK</recordid><startdate>200611</startdate><enddate>200611</enddate><creator>Yang, Feng-Chun</creator><creator>Chen, Shi</creator><creator>Robling, Alexander G</creator><creator>Yu, Xijie</creator><creator>Nebesio, Todd D</creator><creator>Yan, Jincheng</creator><creator>Morgan, Trent</creator><creator>Li, Xiaohong</creator><creator>Yuan, Jin</creator><creator>Hock, Janet</creator><creator>Ingram, David A</creator><creator>Clapp, D Wade</creator><general>American Society for Clinical Investigation</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>200611</creationdate><title>Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions</title><author>Yang, Feng-Chun ; Chen, Shi ; Robling, Alexander G ; Yu, Xijie ; Nebesio, Todd D ; Yan, Jincheng ; Morgan, Trent ; Li, Xiaohong ; Yuan, Jin ; Hock, Janet ; Ingram, David A ; Clapp, D Wade</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2812-c26a76a5f84b758f962fc29f1513a7cd917c85f433d235bbfbd94e283f1f97ee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Animals</topic><topic>Bone Resorption</topic><topic>Cell Differentiation</topic><topic>Cell Nucleus - genetics</topic><topic>Cell Survival</topic><topic>Cells, Cultured</topic><topic>Chromones - pharmacology</topic><topic>Enzyme Activation</topic><topic>GTP Phosphohydrolases - metabolism</topic><topic>Haplotypes</topic><topic>Humans</topic><topic>Macrophage Colony-Stimulating Factor - pharmacology</topic><topic>Mice</topic><topic>Mice, Knockout</topic><topic>Morpholines - pharmacology</topic><topic>Neurofibromatosis 1 - genetics</topic><topic>Neurofibromatosis 1 - metabolism</topic><topic>Neurofibromatosis 1 - pathology</topic><topic>Neurofibromin 1 - deficiency</topic><topic>Neurofibromin 1 - genetics</topic><topic>Neurofibromin 1 - metabolism</topic><topic>Osteoclasts - drug effects</topic><topic>Osteoclasts - metabolism</topic><topic>Osteoclasts - pathology</topic><topic>Phosphatidylinositol 3-Kinases - genetics</topic><topic>Phosphatidylinositol 3-Kinases - metabolism</topic><topic>Proto-Oncogene Proteins p21(ras) - metabolism</topic><topic>RANK Ligand - pharmacology</topic><topic>Stem Cells - metabolism</topic><topic>Stem Cells - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, Feng-Chun</creatorcontrib><creatorcontrib>Chen, Shi</creatorcontrib><creatorcontrib>Robling, Alexander G</creatorcontrib><creatorcontrib>Yu, Xijie</creatorcontrib><creatorcontrib>Nebesio, Todd D</creatorcontrib><creatorcontrib>Yan, Jincheng</creatorcontrib><creatorcontrib>Morgan, Trent</creatorcontrib><creatorcontrib>Li, Xiaohong</creatorcontrib><creatorcontrib>Yuan, Jin</creatorcontrib><creatorcontrib>Hock, Janet</creatorcontrib><creatorcontrib>Ingram, David A</creatorcontrib><creatorcontrib>Clapp, D Wade</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of clinical investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, Feng-Chun</au><au>Chen, Shi</au><au>Robling, Alexander G</au><au>Yu, Xijie</au><au>Nebesio, Todd D</au><au>Yan, Jincheng</au><au>Morgan, Trent</au><au>Li, Xiaohong</au><au>Yuan, Jin</au><au>Hock, Janet</au><au>Ingram, David A</au><au>Clapp, D Wade</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions</atitle><jtitle>The Journal of clinical investigation</jtitle><addtitle>J Clin Invest</addtitle><date>2006-11</date><risdate>2006</risdate><volume>116</volume><issue>11</issue><spage>2880</spage><epage>2891</epage><pages>2880-2891</pages><issn>0021-9738</issn><abstract>Individuals with neurofibromatosis type 1 (NF1) have a high incidence of osteoporosis and osteopenia. However, understanding of the cellular and molecular basis of these sequelae is incomplete. Osteoclasts are specialized myeloid cells that are the principal bone-resorbing cells of the skeleton. We found that Nf1(+/-) mice contain elevated numbers of multinucleated osteoclasts. Both osteoclasts and osteoclast progenitors from Nf1(+/-) mice were hyperresponsive to limiting concentrations of M-CSF and receptor activator of NF-kappaB ligand (RANKL) levels. M-CSF-stimulated p21(ras)-GTP and Akt phosphorylation was elevated in Nf1(+/-) osteoclasts associated with gains of function in survival, proliferation, migration, adhesion, and lytic activity. These gains of function are associated with more severe bone loss following ovariectomy as compared with that in syngeneic WT mice. Intercrossing Nf1(+/-) mice and mice deficient in class 1(A) PI3K (p85alpha) restored elevated PI3K activity and Nf1(+/-) osteoclast functions to WT levels. Furthermore, in vitro-differentiated osteoclasts from NF1 patients also displayed elevated Ras/PI3K activity and increased lytic activity analogous to those in murine Nf1(+/-) osteoclasts. Collectively, our results identify a what we believe to be a novel cellular and biochemical NF1-haploinsufficient phenotype in osteoclasts that has potential implications for the pathogenesis of NF1 bone disease.</abstract><cop>United States</cop><pub>American Society for Clinical Investigation</pub><pmid>17053831</pmid><doi>10.1172/jci29092</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0021-9738 |
ispartof | The Journal of clinical investigation, 2006-11, Vol.116 (11), p.2880-2891 |
issn | 0021-9738 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1616197 |
source | PubMed Central; EZB Electronic Journals Library |
subjects | Animals Bone Resorption Cell Differentiation Cell Nucleus - genetics Cell Survival Cells, Cultured Chromones - pharmacology Enzyme Activation GTP Phosphohydrolases - metabolism Haplotypes Humans Macrophage Colony-Stimulating Factor - pharmacology Mice Mice, Knockout Morpholines - pharmacology Neurofibromatosis 1 - genetics Neurofibromatosis 1 - metabolism Neurofibromatosis 1 - pathology Neurofibromin 1 - deficiency Neurofibromin 1 - genetics Neurofibromin 1 - metabolism Osteoclasts - drug effects Osteoclasts - metabolism Osteoclasts - pathology Phosphatidylinositol 3-Kinases - genetics Phosphatidylinositol 3-Kinases - metabolism Proto-Oncogene Proteins p21(ras) - metabolism RANK Ligand - pharmacology Stem Cells - metabolism Stem Cells - pathology |
title | Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T18%3A01%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hyperactivation%20of%20p21ras%20and%20PI3K%20cooperate%20to%20alter%20murine%20and%20human%20neurofibromatosis%20type%201-haploinsufficient%20osteoclast%20functions&rft.jtitle=The%20Journal%20of%20clinical%20investigation&rft.au=Yang,%20Feng-Chun&rft.date=2006-11&rft.volume=116&rft.issue=11&rft.spage=2880&rft.epage=2891&rft.pages=2880-2891&rft.issn=0021-9738&rft_id=info:doi/10.1172/jci29092&rft_dat=%3Cproquest_pubme%3E68107939%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2812-c26a76a5f84b758f962fc29f1513a7cd917c85f433d235bbfbd94e283f1f97ee3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=68107939&rft_id=info:pmid/17053831&rfr_iscdi=true |